Company intelligence / Profile preview

Panolos Bioscience

Seongnam, Gyeonggi-do, South Koreapanolos.com ↗

Ownership: Private
Employees: ~50
Development stage: Phase 1

Overview

PB101 has received Phase I IND Approval and is being evaluated for Hepatocellular Carcinoma. The company has presented PB101 ICI combination effect data at AACR in 2022.

Therapeutic areas: GastroenterologyOncologyImmunologyRare Diseases
Modalities: Multi-specific antibodiesAntibody fusion proteinsBiological products
Industry: Biotech

Drug pipeline

2 assets

VEGF-Grab

1 more asset in the full pipeline.

Partnerships

Kelun-Biotech (PB203 co-development, 2022)Chime Biologics (strategic cooperation for PB203)Samsung Biologics (CDMO for PB101)Neoimmunetech (joint research for Hyleukin-7-PB101 combination therapy)Scripps Korea (MOU for multi-target pancreatic cancer/solid tumor therapeutics)Teraimune (MOU for atopic/autoimmune skin disease drug co-development)Deargen (MOU for AI-based drug co-development)

Beyond the preview

Go deeper on Panolos Bioscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Panolos Bioscience.